Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EBT: 2012-2024

Historic EBT for Ascendis Pharma A (ASND) over the last 13 years, with Dec 2024 value amounting to -$404.0 million.

  • Ascendis Pharma A's EBT rose 37.79% to -$67.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$245.1 million, marking a year-over-year increase of 45.81%. This contributed to the annual value of -$404.0 million for FY2024, which is 20.81% up from last year.
  • As of FY2024, Ascendis Pharma A's EBT stood at -$404.0 million, which was up 20.81% from -$510.2 million recorded in FY2023.
  • Over the past 5 years, Ascendis Pharma A's EBT peaked at -$404.0 million during FY2024, and registered a low of -$589.5 million during FY2022.
  • In the last 3 years, Ascendis Pharma A's EBT had a median value of -$510.2 million in 2023 and averaged -$501.2 million.
  • Per our database at Business Quant, Ascendis Pharma A's EBT plummeted by 219,190.69% in 2020 and then climbed by 20.81% in 2024.
  • Ascendis Pharma A's EBT (Yearly) stood at -$478.6 million in 2020, then grew by 8.23% to -$439.2 million in 2021, then crashed by 34.22% to -$589.5 million in 2022, then rose by 13.46% to -$510.2 million in 2023, then grew by 20.81% to -$404.0 million in 2024.